A Comparison of the Drug Telbivudine (LdT) and Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis.
Completed · Phase 3
Conditions studied: Hepatitis B, Cirrhosis
In brief
This trial is being done to see if the investigational drug, LdT (Telbivudine), is safe and effective in the treatment of hepatitis B infection. In addition to this, we will be looking at the comparison of the effects (good and bad) of LdT and lamivudine.
Key facts
- Study ID
- NCT00275652
- Run by
- Mayo Clinic
- People needed
- 6
- Starts
- 2004-06-01
- Expected to finish
- 2007-08-01
- Last updated by the study team
- 2011-03-23
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Mayo Clinic — Rochester, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.